Proteomic aging clocks hint at geroprotective signals in rentosertib IPF trial

Six proteomic aging clocks applied to serum from a phase 2a rentosertib IPF trial consistently show slowed biological aging in treated groups, but disentangling aging modulation from anti-fibrotic effects remains challenging. The authors use pathway and external aging-data analyses (including UK Biobank) to identify potential anti-aging shifts in senescence and metabolism, supporting the idea of dual-purpose trials that integrate aging endpoints with disease outcomes.